M&A Deal Summary

Enliven Therapeutics Acquires Imara

On October 13, 2022, Enliven Therapeutics acquired life science company Imara

Acquisition Highlights

This is Enliven Therapeutics’ 1st transaction in the Life Science sector.
This is Enliven Therapeutics’ 1st transaction in the United States.
This is Enliven Therapeutics’ 1st transaction in Massachusetts.

M&A Deal Summary
Date	2022-10-13
Target	Imara
Sector	Life Science
Buyer(s)	Enliven Therapeutics
Deal Type	Merger
Advisor(s)	Leerink Partners (Financial) Wilmer Cutler Pickering Hale and Dorr (Legal)

Target

Imara

Boston, Massachusetts, United States

Imara develops novel therapeutics for people living with sickle cell disease and other hemoglobinopathies. Sickle cell disease is a rare, genetic blood disease that causes red blood cells to sickle and become damaged, activating immune cells and blocking blood flow in capillaries, injuring many organs and causing daily pain. Imara is developing IMR-687, a highly selective, potent small-molecule inhibitor of phosphodiesterase-9 (PDE9i), to treat patients with sickle cell disease. Imara was formed in 2016 and is based in Boston, Massachusetts.

Search 214,239 Deals Now

SEARCH BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Try Free

Buyer(S) 1

Buyer